This might be a good time for VRTX longs to take some chips off the table. The enterprise value now exceeds $10B.
Telaprevir will clearly be a big-selling drug, but for how long? The rate of new HCV infections is small, so there will be fewer patients to be treated in 5-10 years than there are today.
Moreover, newer and better HCV protease inhibitors are coming that will, in all likelihood, supplant the first-generation PI's within a few years (#msg-62384804).
Despite scientific success in CF, VRTX is essentially a one-trick pony. For all practical purposes, it’s a short-lived trust fund for Telaprevir profits.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.